Activation of the phosphatidylinositol-3-kinase ( PI3K ) and/or mitogen-activated protein kinase ( MAPK ) pathways results in anti-estrogen resistance in vitro , but a biomarker with clinical validity to predict intrinsic resistance has not been identified .